Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Review

Analysis of the role of the Hippo pathway in cancer

Author: Yanyan Han

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Cancer is a serious health issue in the world due to a large body of cancer-related human deaths, and there is no current treatment available to efficiently treat the disease as the tumor is often diagnosed at a serious stage. Moreover, Cancer cells are often resistant to chemotherapy, radiotherapy, and molecular-targeted therapy. Upon further knowledge of mechanisms of tumorigenesis, aggressiveness, metastasis, and resistance to treatments, it is necessary to detect the disease at an earlier stage and for a better response to therapy. The hippo pathway possesses the unique capacity to lead to tumorigenesis. Mutations and altered expression of its core components (MST1/2, LATS1/2, YAP and TAZ) promote the migration, invasion, malignancy of cancer cells. The biological significance and deregulation of it have received a large body of interests in the past few years. Further understanding of hippo pathway will be responsible for cancer treatment. In this review, we try to discover the function of hippo pathway in different diversity of cancers, and discuss how Hippo pathway contributes to other cellular signaling pathways. Also, we try to describe how microRNAs, circRNAs, and ZNFs regulate hippo pathway in the process of cancer. It is necessary to find new therapy strategies for cancer.
Literature
1.
Zhu C, Li L, Zhao B. The regulation and function of YAP transcription co-activator. Acta Biochim Biophys Sin (Shanghai). 2015;47:16–28.CrossRef
2.
Misra JR, Irvine KD. The Hippo signaling network and its biological functions. Ann Rev Genet. 2018;23(52):65–87.CrossRef
3.
4.
5.
6.
7.
Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–33.PubMedPubMedCentralCrossRef
8.
Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015;17:1218–27.PubMedPubMedCentralCrossRef
9.
Macias MJ, Hyvonen M, Baraldi E, Schultz J, Sudol M, Saraste M, et al. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature. 1996;382:646–9.PubMedCrossRef
10.
Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domaincontaining Yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18:2551–62.PubMedPubMedCentralCrossRef
11.
Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J. 2010;432:461–72.PubMedCrossRef
12.
Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology. 2011;53:2086–96.PubMedCrossRef
13.
Moon S, Kim W, Kim S, Kim Y, Song Y, Bilousov O, et al. Phosphorylation by NLK inhibits YAP-14-3-3- interactions and induces its nuclear localization. EMBO Rep. 2017;18:61–71.PubMedCrossRef
14.
Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, et al. The Hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. J Biol Chem. 2010;285:37159–69.PubMedPubMedCentralCrossRef
15.
Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014;141:1614–26.PubMedCrossRef
16.
17.
Salah Z, Alian A, Aqeilan RI. WW domain-containing proteins: retrospectives and the future. Front Biosci. 2012;17:331–48.CrossRef
18.
Ye F, Zhang M. Structures and target recognition modes of PDZ domains: recurring themes and emerging pictures. Biochem J. 2013;455:1–14.PubMedCrossRef
19.
Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev. 2010;24:290–300.PubMedPubMedCentralCrossRef
20.
Howell M, Borchers C, Milgram SL. Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription. J Biol Chem. 2004;279:26300–6.PubMedCrossRef
21.
Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994;9:2145–52.PubMed
22.
Nam HK, Yoonmi L, Jong IY. Dishevelling Wnt and Hippo. BMB Rep. 2018;51:425–6.CrossRef
23.
Hyun WP, Young CK, Bo Y, Toshiro M, Jung-Soon M, Steven WP, et al. Alternative Wnt signaling activates YAP/TAZ. Cell. 2015;13:780–94.
24.
Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 2015;17:500–10.PubMedPubMedCentralCrossRef
25.
DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 2014;9:495–503.PubMedPubMedCentralCrossRef
26.
Gailite I, Aerne BL, Tapon N. Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system. Proc Natl Acad Sci. 2015;112:5169–78.CrossRef
27.
Ja HK, Kun LG. Interplay between YAP/TAZ and metabolism. Cell Metab. 2018;7(28):196–206.
28.
Saito A, Suzuki HI, Horie M, Ohshima M, Morishita Y, Abiko Y, et al. An integrated expression profiling reveals target genes of TGF-β and TNF-β possibly mediated by microRNAs in lung cancer cells. PLoS ONE. 2013;8:56587.CrossRef
29.
Akira S, Takahide N. Hippo and TGF-βinterplay in the lung field. Am J Physiol Lung Cell Mol Physiol. 2015;309:756–67.
30.
Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol. 2008;10:837–48.PubMedCrossRef
31.
Beyer TA, Weiss A, Khomchuk Y, Huang K, Ogunjimi AA, Varelas X, et al. Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013;5:1611–24.PubMedCrossRef
32.
Shen Z, Stanger BZ. YAP regulates S-phase entry in endothelial cells. PLoS ONE. 2015;10:0117522.
33.
Benham-Pyle BW, Pruitt BL, Nelson WJ. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and beta-catenin activation to drive cell cycle entry. Science. 2015;348:1024–7.PubMedPubMedCentralCrossRef
34.
Ruth N, Chung JT, Hyunbum J, Tamás K, Peter C. Oncogenic KRAS signaling and YAP1/β-catenin: similar cell cycle control in tumor initiation. Semin Cell Dev Biol. 2016;58:79–85.CrossRef
35.
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185–97.PubMedPubMedCentralCrossRef
36.
Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010;29:2147–60.PubMedPubMedCentralCrossRef
37.
Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, et al. ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors. Cancer Cell. 2015;27:797–808.PubMedPubMedCentralCrossRef
38.
Yulian M, Victor D, Michał AS, Yuriy B, Yuriy D, Askold K, et al. Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma. Cent Eur J Urol. 2018;71:295–303.
39.
Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, et al. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2016;91:409–28.PubMedCrossRef
40.
Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, et al. microRNAs in psoriasis. J Invest Dermatol. 2016;136:365–71.PubMedCrossRef
41.
Hai NZ, Qiao QX, Abhimanyu T, Martin OA, Manas C, Arunima G, et al. Endothelial dysfunction in diabetes and hypertension: role of microRNAs and long non-coding RNAs. Life Sci. 2018;15(213):258–68.
42.
Hanif Q, Farooq M, Amin I, Mansoor S, Zhang Y, Khan QM. In silico identification of conserved miRNAs and their selective target gene prediction in indicine (Bos indicus) cattle. PLoS ONE. 2018;26:0206154.
43.
Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, et al. The role of microRNAs in hepatocellular carcinoma. J Cancer. 2018;8:3557–69.CrossRef
44.
Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 2014;74:4170–82.PubMedPubMedCentralCrossRef
45.
Choe MH, Yoon Y, Kim J, Hwang SG, Han YH, Kim JS. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. Cell Death Dis. 2018;29:640.CrossRef
46.
Li Z, Wang G, Feng D, Zu G, Li Y, Shi X, et al. Targeting the miR-665-3p-ATG4B-autophagy axis relieves inflammation and apoptosis in intestinal ischemia/reperfusion. Cell Death Dis. 2018;9:483.PubMedPubMedCentralCrossRef
47.
Hu Y, Yang C, Yang S, Cheng F, Rao J, Wang X. miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB. Cell Death Dis. 2018;20:954.CrossRef
48.
Luo Q, Wei C, Li X, Li J, Chen L, Huang Y, et al. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 2014;31:1096–102.PubMedPubMedCentralCrossRef
49.
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, et al. miR-195 is a key regulator of Raf1 in thyroid cancer. Oncol Targets Ther. 2015;8:3021–8.CrossRef
50.
Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017;8:99757–71.PubMedPubMedCentral
51.
Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088–96.PubMedCrossRef
52.
Bera R, Chiou CY, Yu MC, Peng JM, He CR, Hsu CY, et al. Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis. Hepatology. 2014;59:2238–50.PubMedCrossRef
53.
54.
Cheng L, Wang H, Han S. MiR-3910 promotes the growth and migration of cancer cells in the progression of hepatocellular carcinoma. Dig Dis Sci. 2017;62:2812–20.PubMedCrossRef
55.
Que K, Tong Y, Que G, Li L, Lin H, Huang S, et al. Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep. 2017;38:3376–86.PubMedPubMedCentral
56.
57.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–6.PubMedCrossRef
58.
Lorena V, Maria F, Andrea S, Federica G, Jlenia V, Teresa C, et al. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol. 2017;18:237.CrossRef
59.
Xiao Z, Yan FX, Zi JQ, Wei SZ, Qi W, Yan C, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis. 2018;9:1091.CrossRef
60.
Zhang J, Zhao X, Zhang J, Zheng X, Li F. Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulatingmiR-136/TFCP2/YAP pathway. Biochem Biophys Res Commun. 2018;22:428–33.CrossRef
61.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.PubMedCrossRef
62.
Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 2017;388:208–19.PubMedCrossRef
63.
Panda AC, Grammatikakis I, Kim KM, De S, Martindale JL, Munk R, et al. Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res. 2017;45:4021–35.PubMedCrossRef
64.
65.
Lorena V, Maria F, Andrea S, Federica G, Jlenia V, Teresa C, et al. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biol. 2017;20:237.
66.
Seetharaman S, Flemyng E, Shen J, Conte MR, Ridley AJ. The RNA-binding protein LARP4 regulates cancer cell migration and invasion. Cytoskeleton (Hoboken). 2016;73:680–90.PubMedPubMedCentralCrossRef
67.
Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017;11:151.CrossRef
68.
Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.PubMedPubMedCentralCrossRef
69.
70.
Andreini C, Bertini I, Cavallaro G. Minimal functional sites allow a classification of zinc sites in proteins. PLoS ONE. 2011;6:26325.CrossRef
71.
Eom KS, Cheong JS, Lee SJ. Structural analyses of zinc finger domains for specific interactions with DNA. J Microbiol Biotechnol. 2016;26(12):2019–29.PubMedCrossRef
72.
Krishna SS, Majumdar I, Grishin NV. Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. 2003;15:532–50.CrossRef
73.
Hossain MA, Barrow JJ, Shen Y, Haq MI, Bungert J. Artificial zinc finger DNA binding domains: versatile tools for genome engineering and modulation of gene expression. J Cell Biochem. 2015;116:2435–44.PubMedPubMedCentralCrossRef
74.
Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 2015;43(Database issue):1079–85.CrossRef
75.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics: tissue-based map of the human proteome. Science. 2015;347:1260419.PubMedCrossRef
76.
77.
Verma NK, Gadi A, Maurizi G, Roy UB, Mansukhani A, Basilico C. Myeloid zinc finger 1 and GA binding protein co-operate with Sox2 in regulating the expression of yes-associated protein 1 in cancer cells. Stem Cells. 2017;35:2340–50.PubMedCrossRef
78.
Schelleckes K, Schmitz B, Lenders M, Mewes M, Brand SM, Brand E. ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA. Sci Rep. 2018;8:4230.PubMedPubMedCentralCrossRef
79.
Guske K, et al. Tissue-specific differences in the regulation of KIBRA gene expression involve transcription factor TCF7L2 and a complex alternative promoter system. J Mol Med (Berl). 2014;92:185–96.PubMedCrossRef
80.
Yu FX, Guan KL. The Hippo pathway, regulators and regulations. Genes. 2013;27:355–71.CrossRef
81.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.PubMedCrossRef
82.
Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 2009;66:773–87.PubMedCrossRef
83.
Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun. 2016;15(7):10498.CrossRef
84.
Lei L, Wu J, Gu D, Liu H, Wang S. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells. Tumour Biol. 2016;37:11073–9.PubMedCrossRef
85.
Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, et al. R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability. J Clin Oncol. 2015;33:2303–10.PubMedCrossRef
86.
Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, et al. Tumor-propagating cells and YAP/TAZ activity contribute to lung tumor progression and metastasis. EMBO J. 2014;33:468–81.PubMedPubMedCentralCrossRef
87.
Zhang W, Gao Y, Li F, Tong X, Ren Y, Han X, et al. YAP promotes malignant progression of LKB1-deficient lung adenocarcinoma through downstream regulation of survivin. Cancer Res. 2015;75:4450–7.PubMedCrossRef
88.
Lo Sardo F, Strano S, Blandino G. YAP and TAZ in lung cancer: oncogenic role and clinical targeting. Cancers (Basel). 2018;10(5):137.PubMedCentralCrossRef
89.
Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, et al. Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. EMBO Mol Med. 2016;8:105–16.PubMedPubMedCentralCrossRef
90.
Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, et al. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta. 2015;1852:1540–9.PubMedCrossRef
91.
Malik SA, Khan MS, Dar M, Hussain MU, Shah MA, Shafi SM, et al. Molecular alterations and expression dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma. Pathol Oncol Res. 2018;24:207–14.PubMedCrossRef
92.
Xu CM, Liu WW, Liu CJ, Wen C, Lu HF, Wan FS. MST1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo. Cancer Gene Ther. 2013;20:453–60.PubMedCrossRef
93.
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p213 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509–18.PubMedCrossRef
94.
95.
96.
Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA, et al. A temporal requirement for Hippo signalling in mammary gland differentiation, growth and tumorigenesis. Genes Dev. 2014;28:432–7.PubMedPubMedCentralCrossRef
97.
Rashidian J, Le Scolan E, Ji X, Zhu Q, Mulvihill MM, Nomura D, et al. Ski regulates Hippo and TAZ signalling to suppress breast cancer progression. Sci Signal. 2015;8:14.CrossRef
98.
Li C, Wang S, Xing Z, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19:106–19.PubMedPubMedCentralCrossRef
99.
Xiang L, Gilkes DM, Hu H, Luo W, Bullen JW, Liang H, et al. HIF-1α and TAZ serve as reciprocal co-activators in human breast cancer cells. Oncotarget. 2015;6:11768–78.PubMedPubMedCentral
100.
Bendinelli P, Maroni P, Matteucci E, Luzzati A, Perrucchini G, Desiderio MA, et al. Hypoxia inducible factor-1is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WW domain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur J Cancer. 2013;49:2608–18.PubMedCrossRef
101.
Maroni P, Matteucci E, Drago L, Banfi G, Bendinelli P, Desiderio MA. Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1 stabilization/nuclear translocation in bone metastasis from breast carcinoma. Exp Cell Res. 2015;330:287–99.PubMedCrossRef
102.
Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, et al. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Int J Gastrointest Cancer. 2006;37:103–9.PubMed
103.
Wei K, Alfred SC, Jun Y, Ka FT. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol. 2016;21:1279–88.
104.
Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, et al. Yes-associated protein1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17:2130–9.PubMedCrossRef
105.
Da CL, Xin Y, Zhao J, Luo XD. Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol. 2009;15:4055–61.PubMedPubMedCentralCrossRef
106.
Vitolo MI, Anglin IE, Mahoney WM, Renoud KJ, Gartenhaus RB, Bachman KE, et al. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther. 2007;6:856–63.PubMedCrossRef
107.
Cui ZL, Han FF, Peng XH, Chen X, Luan CY, Han RC, et al. YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl. Int J Immunopathol Pharmacol. 2012;25:989–1001.PubMedCrossRef
108.
Hu X, Xin Y, Xiao Y, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res. 2014;20:805–11.PubMedCrossRef
109.
Sun L, Chen F, Shi W, Qi L, Zhao Z, Zhang J. Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol. 2014;9:125.PubMedPubMedCentralCrossRef
110.
Wang C, Zhu ZM, Liu CL, He XJ, Zhang HY, Dong JH. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep. 2015;11:4101–8.PubMedPubMedCentralCrossRef
111.
112.
Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014;2014:261–365.
113.
Shimomura T, Miyamura N, Hata S, Miura R, Hirayama J, Nishina H. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity. Biochem Biophys Res Commun. 2014;443:917–23.PubMedCrossRef
114.
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He J, et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology. 2013;58:1011–20.PubMedCrossRef
115.
Li L, Wang J, Zhang Y, Zhang Y, Ma L, Weng W, et al. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 2013;587:3921–7.PubMedCrossRef
116.
Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal. 2013;6:77.CrossRef
117.
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014;33:1468–74.PubMedCrossRef
118.
Philips GK, Atkins MB. New agents and new targets for renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2014;222:7.
119.
Schutte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, et al. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. Transl Oncol. 2014;7:309–21.PubMedPubMedCentralCrossRef
120.
Cao JJ, Zhao XM, Wang DL, Chen KH, Sheng X, Li WB, et al. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis. Oncol Rep. 2014;32:1594–600.PubMedCrossRef
121.
Morris ZS, McClatchey AI. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci. 2009;106:9767–72.PubMedCrossRefPubMedCentral
122.
Wong JS, Meliambro K, Ray J, Campbell KN. Hippo signaling in the kidney: the good and the bad. Am J Physiol Renal Physiol. 2016;1:241–8.CrossRef
123.
124.
125.
Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS ONE. 2013;8:54211.CrossRef
126.
Wierzbicki PM, Rybarczyk A. The Hippo pathway in colorectal cancer. Folia Histochem Cytobiol. 2015;53:105–19.PubMedCrossRef
127.
128.
Gibault F, Corvaisier M, Bailly F, Huet G, Melnyk P, Cotelle P. Non-photoinduced biological properties of verteporfin. Curr Med Chem. 2016;23:1171–84.PubMedCrossRef
129.
Li H, Huang Z, Gao M, Huang N, Luo Z, Shen H, et al. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. J Exp Clin Cancer Res. 2016;35:134.PubMedPubMedCentralCrossRef
130.
Chen M, Wang J, Yao SF, Zhao Y, Liu L, Li LW, et al. Effect of YAP inhibition on human leukemia HL-60 cells. Int J Med Sci. 2017;20:902–10.CrossRef
131.
Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599–606.PubMedPubMedCentralCrossRef
132.
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell. 2007;12:131–44.PubMedPubMedCentralCrossRef
133.
Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116:56–65.CrossRef
134.
Chai J, Xu S, Guo F. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Biochem Biophys Res Commun. 2017;488(2):297–302.PubMedCrossRef
135.
Basu-Roy U, Han E, Rattanakorn K, Gadi A, Verma N, Maurizi G. PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptionalactivity. Oncotarget. 2016;7(38):60954–70.PubMedPubMedCentralCrossRef
136.
137.
Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell. 2014;26(2):273–87.PubMedCrossRef
138.
139.
Abdalla M, Congshan S, Vanessa DM, Joanna S, Edoardo M, Janet S, et al. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma. J Pathol. 2016;240:3–14.CrossRef
140.
Masayuki T, Takao K, Taisuke M, Akihiko Y, Kayo K, Aoi O, et al. Survivin: a novel marker and potential therapeutic target for human angiosarcoma. Cancer Sci. 2017;108(11):2295–305.CrossRef
141.
Konishi H, Kikuchi S, Ochiai T, Ikoma H, Kubota T, Ichikawa D, et al. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastriccancer in mice. Anticancer Res. 2009;29(6):2091–7.PubMed
142.
Leonel C, Ferreira LC, Borin TF, Moschetta MG, Freitas GS, Haddad MR, et al. Inhibition of epithelial–mesenchymal transition in response to treatment with metformin and Y27632 in breast cancer cell lines. Anticancer Agents Med Chem. 2017;17(8):1113–25.PubMedCrossRef
143.
144.
145.
Li J, Wang H, Wang L, Tan R, Zhu M, Zhong X, et al. Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signalingpathway. Phytother Res. 2018;32(12):2456–65.PubMedCrossRef
146.
Chai Y, Xiang K, Wu Y, Zhang T, Liu Y, Liu X, et al. Cucurbitacin B inhibits the Hippo-YAP signaling pathway and exerts anticancer activity in colorectal cancer cells. Med Sci Monit. 2018;24:9251–8.PubMedPubMedCentralCrossRef
147.
148.
Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K, et al. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladdercancer cells. Int J Mol Sci. 2014;15(9):15173–87.PubMedPubMedCentralCrossRef
149.
Dong L, Lin F, Wu W, Liu Y, Huang W. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signalingpathway. Int J Med Sci. 2018;15(6):645–52.PubMedPubMedCentralCrossRef
150.
151.
Metadata
Title
Analysis of the role of the Hippo pathway in cancer
Author
Yanyan Han
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1869-4

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue

Research

m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance

Research

Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment

Research

The epigenome as a putative target for skin repair: the HDAC inhibitor Trichostatin A modulates myeloid progenitor plasticity and behavior and improves wound healing

Research

WBNPMD: weighted bipartite network projection for microRNA-disease association prediction

Research

RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer

Research

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits